收益及经调整毛利增加主要是由于：(i)通过平台创新和自动化升级，特别是蛋白质和基因编辑平台，实 现可靠、快速、优质的服务及产品交付;(ii)中国内地、新加坡及美国生产基地运营效率进一步提升;及 (iii)通过开展有针对性的活动和品牌重塑提升客户参与度。经调整经营利润减少是由于对营销转型及研 究与开发活动的投资增加，以打造中长期竞争力。 金斯瑞生物科技(01548)发布截至2025年6月30日止六个月的未经审核合并中期业绩，持续经营业务收益 5.19亿美元，同比增加81.92%;母公司拥有人应占亏损2546.2万美元，同比收窄85.46%;每股基本亏损1.18 美分。 公告称，报告期内生命科学服务及产品的收益约为2.48亿美元，较上期的约2.22亿美元增加11.3%。经 调整毛利约为1.26亿美元，较上期的约1.2亿美元增加5.3%。经调整毛利率由上期的53.9%略降至 51.0%。经调整经营利润由上期的约4780万美元略降至约4640万美元。 ...

Financial Data and Key Metrics Changes - Q2 GAAP revenue was $27 million, up from $21 million in Q1 2025 and $25 million in Q2 2024, reflecting a 30% sequential increase and an 8% year-over-year increase [5][16] - Excluding one-time adjustments, revenue grew 22% quarter-over-quarter and 4% year-over-year [5][16] - Q2 adjusted EBITDA loss was $10 million, an improvement from a loss of $16 million in Q1 2025 and a loss of $13 million in Q2 2024, representing a 36% improvement quarter-over-quarter and 17% year-over-year [6][18] - Q2 net loss was $9 million compared to a net income of $26 million in the same quarter last year, with an adjusted EBITDA loss improving by $3 million year-over-year [18] Business Line Data and Key Metrics Changes - Paying Monthly Active Users (MAU) reached 146,000, up from 124,000 in Q1 2025 and 122,000 in Q2 2024, indicating an 18% growth quarter-over-quarter and 20% growth year-over-year [5][16] - The paid user conversion rate increased to 19% in Q2 from 15% a year ago [17] Market Data and Key Metrics Changes - User acquisition marketing expenses in Q2 were $3 million, while engagement marketing expenses were $9 million, with total sales and marketing expenses down 16% year-over-year [17] Company Strategy and Development Direction - The company is focused on enhancing its platform to improve player and developer engagement, with significant progress made in loyalty programs and user experience [6][7] - A three-year commitment of $75 million has been made to support a developer accelerator program, aimed at encouraging game development for the platform [9] - The company is also pursuing litigation against competitors for alleged unfair practices, emphasizing its commitment to fair competition [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve positive adjusted EBITDA and highlighted the steady strides being made towards profitability [11][12] - The company believes its current valuation does not reflect the combined value of its operating platform and progress made [15] Other Important Information - The company is working to complete its financial statements for the year ended December 31, 2024, after receiving a notice from the NYSE regarding non-compliance with listing standards [3] - The company ended Q2 with $239 million in cash, providing flexibility to enhance shareholder value [19] Q&A Session Summary - No questions were registered during the Q&A session, and the call concluded without further inquiries [20]